Molecular basis for Pseudomonas aeruginosa persistent infections in CF patients

Mar 12, 2010

New research reveals Small Colony Variants (SCVs) of P. aeruginosa to be a hallmark of chronic infection in cystic fibrosis (CF) patients. Results, published March 12th in the open-access journal PLoS Pathogens, suggest that SCV-mediated persistence might be a good target for antimicrobial chemotherapy.

Cystic fibrosis is a widespread genetic disease that leads to progressive disability and early death. The principal cause of and in CF patients is a progressive deterioration of the respiratory system caused by a chronic infection of the patients' lungs, mainly by the opportunistic bacterial pathogen . CF lung infections can be treated with antibiotics, however full clearance is not possible due to the protective environment of the CF lung and the adaptation of infective species to a persistent lifestyle. This presents serious challenges for the long-term chemotherapy of CF patients.

Adaptive P. aeruginosa morphotypes include SCVs, slow-growing and strongly adherent variants that frequently arise in chronic lung infections. Because the appearance of SCVs correlates with poor lung function and , they have long been suspected of mediating the P. aeruginosa persistence phenotype in CF infections.

In this study, the researchers characterized a signaling system in P. aeruginosa called YfiBNR, mutations in which lead to the generation of SCV variants. Activation of YfiBNR resulted in increased levels of the signaling molecule c-di-GMP, which in turn triggered massive production of exopolysaccharides and drastically reduced growth rates, two hallmarks of SCV behavior. YfiN-mediated SCVs were shown to be highly resistant to macrophage phagocytosis, suggesting a role for the SCV phenotype in immune system evasion. Consistent with this, activation of YfiN significantly increased the persistence of P. aeruginosa in long-term infections in a mouse model, establishing a firm causal link between SCV and persistence in chronic P. aeruginosa infections.

The authors conclude that 'c-di-GMP has long been a key suspect in chronic behavior of bacterial pathogens. The finding that the c-di-GMP-mediated SCV phenotype confers a persistent advantage in mice provides the first direct evidence in favor of such a model. This study thus opens up new avenues to specifically counteract persistent infections.'

Explore further: Ultrasound enhancement provides clarity to damaged tendons, ligaments

More information: Malone JG, Jaeger T, Spangler C, Ritz D, Spang A, et al. (2010) YfiBNR Mediates Cyclic di-GMP Dependent Small Colony Variant Formation and Persistence in Pseudomonas aeruginosa. PLoS Pathog 6(3): e1000804. doi:10.1371/journal.ppat.1000804

add to favorites email to friend print save as pdf

Related Stories

Bacteria 'launch a shield' to resist attack

Nov 02, 2009

Bacteria that cause chronic lung infections can communicate with each other to form a deadly shield against the body's natural defenses. Studying these interactions could lead to new ways of treating bacteria that are resistant ...

Research promising for cystic fibrosis

Mar 18, 2008

New University of Toronto research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus.

No hiding place for infecting bacteria

Mar 16, 2009

Scientists in Colorado have discovered a new approach to prevent bacterial infections from taking hold. Writing in the Journal of Medical Microbiology, Dr Quinn Parks and colleagues describe how they used enzymes against produc ...

Garlic hope in infection fight

Jan 31, 2007

Garlic has been hailed a wonder drug for centuries and has been used to prevent gangrene, treat high blood pressure, ward off common colds and is even believed by some to have cancer-fighting properties.

Recommended for you

A better way to track emerging cell therapies using MRIs

Sep 19, 2014

Cellular therapeutics – using intact cells to treat and cure disease – is a hugely promising new approach in medicine but it is hindered by the inability of doctors and scientists to effectively track the movements, destination ...

User comments : 0